Effects and Safety of Liposome Encapsulated Botulinum Toxin A for Overactive Bladder Syndrome

• ClinicalTrials.gov Identifier: NCT01167257
• Recruitment Status: Completed
• First Posted: July 22, 2010
• Results First Posted: September 22, 2014
• Last Update Posted: September 22, 2014
• Sponsor: Buddhist Tzu Chi General Hospital
• Information provided by (Responsible Party): Hann-Chorng Kuo, Buddhist Tzu Chi General Hospital

Study Description

Brief Summary:

Overactive bladder (OAB) is a bothered symptom syndrome. Traditional medication for OAB is antimuscarinic agent. However, adverse events such as dry mouth, constipation, blurred vision, and dizziness may prohibit patient to take this drug for OAB. Intravesical botulinum toxin A (BoNT-A) is a novel treatment however, BoNT-A can cause acute urinary retention and large postvoid residual. In this grant we will evaluate liquid liposome delivery of BoNT-A (Liposome encapsulated BoNT-A) into the bladder without the need for cystoscopic-guided needle injection for refractory OAB.

Condition or disease	Intervention/treatment	Phase
Overactive Bladder	Drug: Liposome encapsulated botulinum toxin A; Drug: Normal saline instillation	Phase 2

Detailed Description:

Overactive bladder (OAB) is a symptom syndrome characterized by urgency frequency with or without urgency incontinence, usually no metabolic or anatomical disorders can be found and it may have great impact on quality of life. Traditional medication for OAB is antimuscarinic agent which targets at the muscarinic receptors. There are several adverse events such as dry mouth, constipation, blurred vision, and dizziness related to antimuscarinics, therefore, some patients cannot tolerated this treatment. Intravesical botulinum toxin A (BoNT-A) has recently emerged as novel treatment for OAB refractory to antimuscarinics, however, BoNT-A injection can cause acute urinary retention and large postvoid residual. Urinary tract infection usually occurred following large postvoid residual and urinary retention. If we can deliver BoNT-A through the urothelium to the suburothelial space, but not into the detrusor layer, we might have therapeutic effects on the urothelial sensory nerves without compromising the detrusor contractility. This treatment will enable us to prevent the undesired detrusor underactivity after BoNT-A injection, especially in the elderly patients who had impaired detrusor contractility and OAB. Liposomes are vesicles, composed of concentric phospholipid bilayers separated by aqueous compartments. Because liposomes adsorb to cell surfaces and fuse with cells, they are being used as vehicles for drug delivery and gene therapy. In this grant we will evaluate liquid liposome delivery of BoNT-A (Liposome encapsulated BoNT-A) into the bladder without the need for cystoscopic-guided needle injection for refractory OAB, and study the mechanism of action of intravesical liposomal drug delivery. If successful, we will leverage our technology transfer expertise and bring the science from the bench top to the bed side to apply for a physician sponsored Investigational New Drug (IND) trial using liposome-BoNT in patients with OAB or DO.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 62 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Treatment
• Official Title: Comparative Study of the Efficacy and Safety of Liposome Encapsulated Botulinum Toxin-A (Lipotoxin) Versus Normal Saline Instillation in Treatment of Patients With Refractory Overactive Bladder Syndrome
• Study Start Date: May 2010
• Actual Primary Completion Date: December 2013
• Actual Study Completion Date: December 2013

Arms and Interventions

Arm	Intervention/treatment
Experimental: Experimental arm; Liposome encapsulated BoNT-A ( mixed BOTOX 200 U/10 mL in Liposome 80 mg/40 mL) in single intravesical instillation Liposome encapsulated botulinum toxin A'	Drug: Liposome encapsulated botulinum toxin A; Liposome encapsulated BoNT-A ( mixed BOTOX 200 U/10 mL water in Liposome 80 mg/40 mL water) in single intravesical instillation, one time treatment at the treatment day; Other Name: Lipotoxin
Placebo Comparator: Control arm; Normal saline 50 mL in single intravesical instillation Normal saline instillation'	Drug: Normal saline instillation; Normal saline (BoNT-A/NS) 50 mL in single intravesical instillation; Other Name: N/S

Outcome Measures

Primary Outcome Measures :

1. Mean Change of the Total Frequency Per 3 Days [ Time Frame: Baseline to 4 weeks after initial treatment ]

   Efficacy:

   Mean change of the total frequency per 3 days from baseline to 4 weeks after the treatment day based on the 3-day voiding diary.

   Change = Week 4 minus Baseline value

Secondary Outcome Measures :

1. Mean Change of the Urgency Episodes Per 3 Days [ Time Frame: Baseline to 4 weeks after initial treatment ]

   Efficacy:

   Mean change of the Urgency episodes per 3 days from baseline to 4 weeks after the treatment day based on the 3-day voiding diary.

   Change = Week 4 minus Baseline value

2. Mean Change of the Urgency Urinary Incontinence (UUI) Per 3 Days [ Time Frame: Baseline to 4 weeks after initial treatment ]

   Efficacy:

   Mean change of the urgency urinary incontinence (UUI) per 3 days from baseline to 4 weeks after the treatment day based on the 3-day voiding diary.

   Change = Week 4 minus Baseline value

3. Net Change of the Overactive Bladder Symptom Score (OABSS) [ Time Frame: Baseline to 4 weeks after initial treatment ]

   Efficacy:(measured the net change of variables from baseline to 1 month) Overactive bladder symptom score (OABSS) The OABSS is a 4-item questionnaire developed to evaluate OAB symptoms. The maximal scores are 2, 3, 5 and 5 for daytime frequency, nighttime frequency, urgency and urgency in continence, respectively.

   The OABSS range = 0 to 15 ((asymptomatic to very symptomatic). Change = Week 4 minus Baseline value

4. Net Change of the Functional Bladder Capacity (FBC) [ Time Frame: Baseline to 4 weeks after initial treatment ]
   Efficacy:(measured the net change of variables from baseline and 1 month) Functional bladder capacity (FBC) Change = Week 4 minus Baseline value
5. Net Change of the Maximum Flow Rate (Qmax) [ Time Frame: Baseline to 4 weeks after initial treatment ]
   Efficacy:(measured the net change of variables from baseline and 1 month) Maximum flow rate (Qmax) Change = Week 4 minus Baseline value
6. Net Change of the Postvoid Residual Volume (PVR) [ Time Frame: Baseline and 1 month after initial treatment ]
   Efficacy:(measured the net change of variables from baseline and 1 month) Postvoid residual volume (PVR) Change = Week 4 minus Baseline value
7. Net Change of the Urgency Severity Score (USS) Within 3 Days [ Time Frame: Baseline to 4 weeks after initial treatment ]
   Efficacy:(measured the net change of variables from baseline and 1 month) Urgency severity score (USS) within 3 days. The USS have 1-point scale ranging from 0 to 4. The USS grades urgency per toilet void as none, mild, moderate or severe.
8. Net Change of the Global Response Assessment (GRA) [ Time Frame: Baseline to 4 weeks after initial treatment ]
   Efficacy:(measured the net change of variables from baseline and 1 month) The Global response assessment (GRA) have seven point scale is centered at zero (no change): markedly worse; moderately worse; slightly worse; no change; slightly improved; moderately improved; and markedly improved.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Adults with age of 20 years old or above
2. Patients with symptoms of urgency frequency and/or urge incontinence and a urgency severity scale (USS) of at least 2, with or without urodynamically proven detrusor overactivity (DO) (defined by the International Continence Society (ICS) recommendation as: spontaneous detrusor contraction occurring during bladder filling phase or occurring before uninhibited detrusor contraction voiding at bladder capacity in the urodynamic study)
3. Free of active urinary tract infection
4. Free of bladder outlet obstruction on enrollment
5. Free of overt neurogenic bladder dysfunction
6. Having been treated with antimuscarinic agents for at least 4 weeks without effect or with intolerable adverse effects
7. Patient has not been treated with bladder surgery for OAB, such as enterocystoplasty, that might affect the therapeutic effect of test drug
8. Patient can record voiding diary for the urinary frequency and urgency
9. Patient or his/her legally acceptable representative has signed the written informed consent form

Exclusion Criteria:

1. Use of antimuscarinic agent and effective in treatment of lower urinary tract symptoms
2. Patients with severe cardiopulmonary disease and such as congestive heart failure, arrhythmia, poorly controlled hypertension, not able to receive regular follow-up
3. Patients with bladder outlet obstruction on enrollment
4. Patients with postvoid residual >150 mL
5. Patients with uncontrolled confirmed diagnosis of acute urinary tract infection

6. Patients have laboratory abnormalities at screening including:

   Alanine aminotransferase (ALT) >3 x upper limit of normal range Aspartate aminotransferase (AST) >3 x upper limit of normal range Patients have abnormal serum creatinine level >2 x upper limit of normal range

7. Patients with any contraindication to be urethral catheterization during treatment
8. Female patients who is pregnant, lactating, or with child-bearing potential without contraception.
9. Myasthenia gravis, Eaton Lambert syndrome.
10. Patients with any other serious disease considered by the investigator not suitable for general anesthesia or in the condition to enter the trial
11. Patients participated investigational drug trial within 1 month before entering this study

Contacts and Locations

Locations

Taiwan

Buddhist Tzu Chi General Hospital

Hualien, Taiwan, 970

Sponsors and Collaborators

Buddhist Tzu Chi General Hospital

Investigators

• Principal Investigator: Hann-Chorng Kuo, M.D.; Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University
• Principal Investigator: Yao-Chi Chuang, M.D.; Department of Urology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan

More Information

• Responsible Party: Hann-Chorng Kuo, Department of Urology, Buddhist Tzu Chi General Hospital
• ClinicalTrials.gov Identifier: NCT01167257
• Other Study ID Numbers: TCGHUROL001
• First Posted: July 22, 2010
• Results First Posted: September 22, 2014
• Last Update Posted: September 22, 2014
• Last Verified: September 2014

Keywords provided by Hann-Chorng Kuo, Buddhist Tzu Chi General Hospital:

Overactive bladder; Detrusor overactivity; Liposome; Botulinum toxin A

Additional relevant MeSH terms:

Urinary Bladder, Overactive; Urinary Bladder Diseases; Urologic Diseases; Lower Urinary Tract Symptoms; Urological Manifestations; Botulinum Toxins; Botulinum Toxins, Type A; abobotulinumtoxinA; Acetylcholine Release Inhibitors; Membrane Transport Modulators; Molecular Mechanisms of Pharmacological Action; Cholinergic Agents; Neurotransmitter Agents; Physiological Effects of Drugs; Neuromuscular Agents; Peripheral Nervous System Agents